Literature DB >> 31522233

Familial mediterranean fever: assessment of clinical manifestations, pregnancy, genetic mutational analyses, and disease severity in a national cohort.

Hatice Bodur1, Fatma Gül Yurdakul2, Hasan Fatih Çay3, Ülkü Uçar3,4, Yaşar Keskin5, Betül Sargın6,7, Gülcan Gürer6, Ozan Volkan Yurdakul5, Mustafa Çalış8, Hülya Deveci9, Yıldıray Aydın10, Sami Hizmetli11, Remzi Çevik12, Ali Yavuz Karahan13, İsmihan Sunar14, Mehmet Tuncay Duruöz15, Hilal Ecesoy16, Zafer Günendi17, Murat Toprak18, Nesrin Şen19, Duygu Altıntaş20, Ahmet Kıvanç Cengiz21,22, Gökhan Çağlayan11, Ali Nail Demir23, Hüseyin Kaplan8,24, Sertaç Ketenci25, Meltem Alkan Melikoğlu20, Mehmet Nayimoğlu26, Kemal Nas27, Ayşe Banu Sarıfakıoğlu26, İlhan Sezer23.   

Abstract

The aims of this study were to investigate the main clinical and laboratory features, including pregnancy and genetic analysis, of Turkish Familial Mediterranean Fever (FMF) patients and to analyze the relationships between genotypic features, age of disease onset, clinical findings, and disease severity. A study was planned within a national network of 22 different centers. Demographics, clinical and laboratory findings, attack characteristics, drugs, pregnancy and birth history, disease severity, and gene mutation analyses were evaluated. Disease severity, assessed using a scoring system developed by Pras et al., was evaluated in relation to gene mutations and age of disease onset. A total of 979 patients (643 females and 336 males; mean age: 35.92 ± 11.97 years) with FMF were included in the study. Of a total of 585 pregnancies, 7% of them resulted in preterm birth and 18.1% resulted in abortions. During pregnancy, there was no FMF attack in 61.4% of patients. Of the MEditerranean FeVer (MEFV) mutations, 150 (24.3%) cases were homozygous, 292 (47.3%) cases were heterozygous, and 175 (28.4%) were compound heterozygous. Patients with homozygous gene mutations had more severe disease activity, earlier age of disease onset, higher rates of joint and skin involvement, sacroiliitis, and amyloidosis. Patients with compound heterozygous genotype displayed severe disease activity in close resemblance to patients with homozygous mutation. In addition, patients with compound heterozygous mutations had higher rates of protracted febrile myalgia and elevated fibrinogen levels. In 63.9% of compound heterozygous patients, age of onset was < 20 years, with greater disease severity, and high rates of attack frequency and colchicine resistance. Our results suggest that indicators for disease severity include early onset of disease and homozygous gene mutations. Furthermore, patients with compound heterozygous mutations displayed significant presentations of severe disease activity.

Entities:  

Keywords:  Amyloidosis; Colchicine; Mutation; Pregnancy

Mesh:

Substances:

Year:  2019        PMID: 31522233     DOI: 10.1007/s00296-019-04443-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  29 in total

1.  Characteristics of patients with adult-onset familial Mediterranean fever in Turkey: analysis of 401 cases.

Authors:  M Sayarlioglu; A Cefle; M Inanc; S Kamali; E Dalkilic; A Gul; L Ocal; O Aral; M Konice
Journal:  Int J Clin Pract       Date:  2005-02       Impact factor: 2.503

2.  Is E148Q a benign polymorphism or a disease-causing mutation?

Authors:  Dina Marek-Yagel; Ifat Bar-Joseph; Elon Pras; Yackov Berkun
Journal:  J Rheumatol       Date:  2009-10       Impact factor: 4.666

3.  Familial Mediterranean fever gene mutation frequencies in a sample Turkish population.

Authors:  Oguz Soylemezoglu; Yasar Kandur; Sevim Gonen; Ali Düzova; Zeynep Birsin Özçakar; Kibriya Fidan; Fatos Yalcinkaya
Journal:  Clin Exp Rheumatol       Date:  2016-10-17       Impact factor: 4.473

Review 4.  Update on the epidemiology and disease outcome of Familial Mediterranean fever.

Authors:  Seza Özen
Journal:  Best Pract Res Clin Rheumatol       Date:  2018-09-29       Impact factor: 4.098

5.  The Influence of Concomitant Disorders on Disease Severity of Familial Mediterranean Fever in Children.

Authors:  Rabia Miray Kişla Ekinci; Sibel Balci; Derya Ufuk Altintaş; Mustafa Yilmaz
Journal:  Arch Rheumatol       Date:  2017-10-30       Impact factor: 1.472

6.  The Frequency of MEFV Gene Mutations and Genotypes in Sanliurfa Province, South-Eastern Region of Turkey, after the Syrian Civil War by Using Next Generation Sequencing and Report of a Novel Exon 4 Mutation (I423T).

Authors:  Evren Gumus
Journal:  J Clin Med       Date:  2018-05-07       Impact factor: 4.241

7.  Assessment of Mean Platelet Volume in Patients with AA Amyloidosis and AA Amyloidosis Secondary to Familial Mediterranean Fever: A Retrospective Chart - Review Study.

Authors:  Ali Bakan; Alihan Oral; Sabahat Alışır Ecder; Gulsah Şaşak Kuzgun; Ömer Celal Elçioğlu; Recep Demirci; Kübra Aydın Bahat; Ali Rıza Odabas
Journal:  Med Sci Monit       Date:  2019-05-24

Review 8.  Use of colchicine in pregnancy: a systematic review and meta-analysis.

Authors:  Praveen L Indraratna; Sohaib Virk; Divya Gurram; Richard O Day
Journal:  Rheumatology (Oxford)       Date:  2018-02-01       Impact factor: 7.580

9.  Adult-onset familial mediterranean Fever in northwestern iran; clinical feature and treatment outcome.

Authors:  H Nobakht; F Zamani; H Ajdarkosh; Z Mohamadzadeh; Sm Fereshtehnejad; M Nassaji
Journal:  Middle East J Dig Dis       Date:  2011-03

10.  Musculoskeletal manifestations occur predominantly in patients with later-onset familial Mediterranean fever: Data from a multicenter, prospective national cohort study in Japan.

Authors:  Yushiro Endo; Tomohiro Koga; Midori Ishida; Yuya Fujita; Sosuke Tsuji; Ayuko Takatani; Toshimasa Shimizu; Remi Sumiyoshi; Takashi Igawa; Masataka Umeda; Shoichi Fukui; Ayako Nishino; Shin-Ya Kawashiri; Naoki Iwamoto; Kunihiro Ichinose; Mami Tamai; Hideki Nakamura; Tomoki Origuchi; Kazunaga Agematsu; Akihiro Yachie; Junya Masumoto; Kiyoshi Migita; Atsushi Kawakami
Journal:  Arthritis Res Ther       Date:  2018-11-20       Impact factor: 5.156

View more
  8 in total

1.  The importance of Mediterranean fever gene in familial Mediterranean fever.

Authors:  Demet Yalçın Kehribar; Metin Özgen
Journal:  Eur J Rheumatol       Date:  2020-07-21

2.  Bibliometric analysis of publication activity in the field of familial Mediterranean fever in 2010-2019: a Scopus-based study.

Authors:  Burhan Fatih Kocyigit; Ahmet Akyol
Journal:  Rheumatol Int       Date:  2021-09-09       Impact factor: 2.631

3.  Clinical and functional impact of central sensitization on patients with familial Mediterranean fever: a cross-sectional study.

Authors:  Feyza Nur Yücel; Halise Hande Gezer; Janbubi Jandaulyet; Nuran Öz; Sevtap Acer Kasman; Mehmet Tuncay Duruöz
Journal:  Rheumatol Int       Date:  2022-08-12       Impact factor: 3.580

4.  Spondyloarthritis in familial Mediterranean fever: a cohort study.

Authors:  Sevtap Acer Kasman; Mehmet Tuncay Duruöz
Journal:  Rheumatol Int       Date:  2022-06-18       Impact factor: 3.580

5.  Investigation of Acceptance of Illness and Religious Coping in Patients with Familial Mediterranean Fever in Turkey.

Authors:  Sibel Şentürk; Alev Yıldırım Keskin; Şule Turan
Journal:  J Relig Health       Date:  2022-05-23

Review 6.  Inflammasome Targeted Therapy in Pregnancy: New Insights From an Analysis of Real-World Data From the FAERS Database and a Systematic Review.

Authors:  Carla Carnovale; Enrico Tombetti; Vera Battini; Faizan Mazhar; Sonia Radice; Mariangela Nivuori; Enrica Negro; Silvia Tamanini; Antonio Brucato
Journal:  Front Pharmacol       Date:  2021-01-20       Impact factor: 5.810

7.  The impact of COVID-19 on familial Mediterranean fever: a nationwide study.

Authors:  Zafer Günendi; Fatma Gül Yurdakul; Hatice Bodur; Ahmet Kıvanç Cengiz; Ülkü Uçar; Hasan Fatih Çay; Nesrin Şen; Yaşar Keskin; Gülcan Gürer; Meltem Alkan Melikoğlu; Duygu Altıntaş; Hülya Deveci; Merve Baykul; Kemal Nas; Remzi Çevik; Ali Yavuz Karahan; Murat Toprak; Sertaç Ketenci; Mehmet Nayimoğlu; İlhan Sezer; Ali Nail Demir; Hilal Ecesoy; Mehmet Tuncay Duruöz; Ozan Volkan Yurdakul; Ayşe Banu Sarıfakıoğlu; Şebnem Ataman
Journal:  Rheumatol Int       Date:  2021-05-25       Impact factor: 2.631

Review 8.  The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease.

Authors:  Eitan Giat; Ilan Ben-Zvi; Merav Lidar; Avi Livneh
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.